Swiss drugmaker Novartis announced plans to invest $23 billion in the United States over the next five years, responding to growing political pressure and potential import tariffs threatened by former President Donald Trump.
The move includes building six new manufacturing plants and expanding four existing ones, with the goal of strengthening its US footprint and increasing local production.
